文献速递泌尿男性生殖肿瘤支持与姑息治疗

化疗激素治疗期间生活质量:E3805随机试验分析

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2018-03-09

E3805试验比较转移性激素敏感性前列腺癌患者接受多西他赛联合雄激素剥夺治疗(ADT+D)与单用ADT的生活质量(QOL)。结果显示ADT+D组3个月时QOL显著下降,但12个月时QOL显著优于ADT组,且差异未超过最小临床重要差异。

要点

  • 两组FACT-P差异均未超过最小临床重要差异。

核心结论

  • ADT+D在3个月时QOL较差,但12个月时QOL优于ADT,长期负面影不显著。

临床怎么用

  • ADT+D治疗早期可能出现QOL下降,但长期QOL不劣于ADT单用,可据此向患者说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the QOL between arms at each time point. Results Seven hundred ninety men were randomly assigned (ADT+D [n = 397] and ADT[ n = 393]) and completed FACT-P (90% at baseline, 86% at 3 months, 83% at 6 months, 78% at 9 months, and 77% at 12 months). ADT+D patients reported a statistically significant decline in FACT-P at 3 months ( P < .001) but FACT-P did not differ significantly between baseline and 12 months ( P = .38). ADT+D FACT-P scores were significantly lower at 3 months ( P = .02) but significantly higher at 12 months ( P = .04) when compared with ADT FACT-P scores. Differences did not exceed the minimal clinically important difference at any time point. ADT+D patients reported significantly lower Functional Assessment of Chronic Illness Therapy-Fatigue scores at 3 months than did ADT patients ( P < .001). Over time, both arms reported significantly poorer FACT-Taxane scores ( P < .001) when compared with baseline. Brief Pain Inventory scores were similar between arms. Conclusion Although ADT+D was associated with statistically worse QOL at 3 months, QOL was better at 12 months for ADT+D patients than for ADT patients. Both arms reported a similar minimally changed QOL over time, suggesting that ADT+D is not associated with a greater long-term negative impact on QOL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Morgans AK, Chen YH, Sweeney CJ, et al. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol. 2018. PMID: 29522362. doi:10.1200/JCO.2017.75.3335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。